- Impact & proof: Where have patient organisations demonstrably changed a policy position, pathway, or decision— what did “impact” look like, and how was it evidenced?
- Health & Wealth: How to engage patients in industrial and economics policy debates that impact their health?
- HTA & technical barriers: HTA is often a “technical nightmare” for patient communities—what would it take to make patient experience a first-class input to evidence generation and assessment?
- Closing the loop: What does a credible “feedback loop” look like—how should institutions and industry show patients exactly what changed (or didn’t) because of their input?
- Definition of success: If we reconvened in 12 months, what specific changes would prove we’ve moved from “input” to “impact”—fewer delays, less postcode variation, clearer decisions, better equity?
Moderator:
Victoria Hayes, Director, Public Affairs, Kyowa Kirin
Panellist:
Dr Lucy McKay, Chief Executive Officer, Medics for Rare Disease
Ron Hillel, Assoc. Director, Representation in Clinical Research, Global Patient Engagement, Novartis